Spinal Muscular Atrophy

New England CEPAC

ICER developed a report assessing the comparative clinical effectiveness and value of onasemnogene abeparvovec (Zolgensma®, Novartis AG/AveXis) and nusinersen (Spinraza®, Biogen) for treatment of spinal muscular atrophy (SMA).

For questions or additional information, please contact info@icer-review.org

Associated Meetings

March 7, 2019 9:30am-4pm ET

Omni Parker House
60 School Street
Boston, MA 02108

The New England CEPAC convened to deliberate and vote on ICER's report on treatments for SMA.


Key Dates

Associated Materials